肝细胞癌的靶向及免疫治疗新进展  

Recent progresses of targeted therapy and immunotherapy of hepatocellular carcinoma

作　　者：江山 徐细明[1] Jiang Shan;Xu Ximing(Cancer Center,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院肿瘤中心,武汉430060

出　　处：《国际肿瘤学杂志》2023年第11期688-695,共8页Journal of International Oncology

摘　　要：肝细胞癌(HCC)是世界上最常见的恶性肿瘤之一,在我国的发病率及病死率居高不下。自从索拉非尼开辟了HCC靶向治疗的新时代,全球的药物研发人员在HCC系统治疗上的探索做出了许多的努力与贡献。近年来,新型分子靶向药物、免疫检查点抑制剂及其联合治疗方案在晚期HCC中进行了许多大样本、国际多中心临床试验。结果显示,免疫联合靶向以及双免疫联合的治疗效果相较于靶向或免疫单药具有显著的优势,在延长生存期、改善患者生命质量的同时也具有令人满意的安全性。Hepatocellular carcinoma(HCC)is one of the most common malignancies in the world,with a high incidence and fatality rate in China.Since sorafenib opened up a new era of targeted therapy for HCC,drug developers around the world have made a lot of efforts and contributions to the exploration of systematic therapy for HCC.In recent years,novel molecular targeted agents,immune checkpoint inhibitors and their combined treatment regimens in advanced HCC have been implemented for many large samples,international multi-center clinical trials.The results show that the therapeutic effect of immunotherapy combined with targeted therapy and dual immunotherapy have significant advantages compared with that of targeted or immune monotherapy,and have satisfactory safety while prolonging survival and improving the quality of life of patients.

关 键 词：癌 肝细胞 分子靶向治疗 免疫疗法 

分 类 号：R735.7[医药卫生—肿瘤]